Side-by-side financials for CTMX and NVS. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CTMX | NVS |
|---|---|---|
| Market cap | - | $292.08 B |
| US-listed rank | - | #47 |
| Revenue (latest FY) | $76.20M | - |
| Net income (latest FY) | -$17.37M | - |
| Net margin | -22.8% | - |
| SEC filings | 773 | 947 |
Full pages: CytomX Therapeutics, Inc. and Novartis AG, or browse the full rankings.